GlassScriptPhysician profile
Jonathan Alvaro
NPI 1811353089
$2,124.75
in general payments reported to CMS, 2019-2025
21 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $188 · 2024: $825 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.63 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.63 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $226.25 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $166.26 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $165.39 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $153.87 | 2024-2025 | Dupixent, Libtayo |
| Incyte Corporation | $142.42 | 2025 | Opzelura, Opzelura |
| Ucb, INC. | $104.93 | 2024-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $103.92 | 2025 | Airsupra |
| Sun Pharmaceutical Industries INC. | $90.93 | 2022-2024 | |
| Galderma Laboratories, L.P. | $66.02 | 2022-2025 | Nemluvio |
| Pfizer INC. | $62.88 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $58.88 | 2024 | Zoryve |
| Lilly USA, LLC | $52.93 | 2024 | Taltz, Olumiant |
| Genzyme Corporation | $51.44 | 2024 | |
| Verrica Pharmaceuticals INC. | $50.46 | 2025 | Ycanth |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $29.53 | 2025 | |
| Amgen INC. | $26.80 | 2022 | |
| Botanix Sb INC | $24.34 | 2025 | Sofdra |
| Lnhc, INC | $18.09 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $16.49 | 2024 | Adbry |
| Abbott Laboratories | $14.29 | 2024 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Alvaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.